08.30 – 09.15 Registration, refreshments and exhibition viewingCHAIR: Sharie FetzerChair, Lipoedema UK09.15 – 09.20 Welcome and introduction by Chair09.20 – 10.00 Genital lymphoedemaPresenter: Jane WiggFor both males and females, genital oedema can have a catastrophic effect on quality of life. This session will discuss the causes, early signs and treatment of genital lymphoedema, demonstrating the use of indocyanine green imaging in improving our knowledge and understanding. It will also revisit treatment possibilities, with impact from real stories, helping you to take steps towards improving the lives of those living with this condition.
10:00 – 10.40 The importance of Skin care and the management of LymphorrhoeaSession Speaker: Kris Jones, Lymphoedema Nurse Specialist/Managing Director LymphCare UK10.40 – 11.10 Refreshments and exhibition viewing11.10 – 11.40 Anogenital Granulomatosis: Recognising and Managing a Rare Cause of LymphoedemaPresenter: Kerri CooperAno-genital granulomatosis is a rare chronic condition of the skin that causes lymphoedema of the external genitalia. Mechanisms of disease and optimal methods of treatment are poorly understood. This presentation provides an insight of a new technique for management derived directly from the speaker’s practice, drawing from clinical experience and real-world patient examples.
11.40 - 12.10 Haddenham Comfiwave: Uses and VersatilityPresenter: Sue Lawrance This session will explore the wide variety of uses of Haddenham Comfiwave garments, as both stand alone and combination options. Case studies of patients with diverse types and causes of lymphoedema will demonstrate positive outcomes, where a wide variety of Comfiwave combinations have been used.
Thinking innovatively in clinical practice will be encouraged, by ensuring a fuller understanding of this product, its profile and its benefits.
12.10 – 12.40 Lipoedema and Mental HealthPresenter: Harriet Berry12:40 – 13:30 Lunch and exhibition viewing13.30 - 14.00 Exploring resource and cost saving opportunities when prescribing compression garmentsThis session will highlight the cost and resource savings that can be achieved when using sized flat knit compression garments instead of custom-made garments in the management of lymphoedema. During the session we will detail the differences in the sized range of flat knit compression products and the indications for using them in clinical practice.
Session Speaker:Natalie Phillips14:00 – 14:30 The impact of 24-hour interval practice on the patientPresenter: Jeanette MuldoonThe 24-hour interval compression plan for managing chronic oedema enables the patient or wearer to take more control on how compression is applied and worn within their daily activities. The effects of this practice on compression device pressures, skin and the wearer’s mood will be discussed, with references to the researcher’s own experiences and other studies that have been conducted internationally.
14:30 - 15:05 Pain and discomfort in breast cancer-related lymphoedemaSession Speaker: Sara Harding, Specialist Lymphoedema Therapist, Royal Marsden Foundation Trust15.05 – 15.35 Refreshments and exhibition viewing15:35 – 16:10 Deep vein thrombosisPresenter: Catriona O’NeillThere is some confusion surrounding the management of people with lymphoedema in the presence of deep vein thrombosis (DVT). This may be in relation to the suitability of commencing compression therapy or regarding the continuation of compression therapy in those who develop DVT. The purpose of the position paper is to support evidence-based practice and debunk myths surrounding the management of DVT and lymphoedema. It is recognised that patients with pre-existing lymphoedema can develop DVTs and also that patients who get DVTs are very likely to develop chronic oedema/lymphoedema as part of post-thrombotic syndrome.
16:10 – 16:35 Obesity and inflammationPresenter: Justine WhitakerSome 62% of the UK population are overweight, and 25% are obese. In the population of lymphoedema patients, according to a recent study, 37.1% are obese and a further 20.7% are morbidly obese. This is a huge challenge for clinicians and patients alike. Is there a link? Does one cause the other? What new science is emerging around this, and what treatments and help can we expect to be able to offer our patients now and in the future? This presentation will look at the above and hopefully enlighten the audience to consider and challenge current practices.
16.35 Close of conference